Nivestim, which was approved in the EU in Jun 2010 (#msg-51176267), is HSP’s second biosimilar product; the first is a knockoff of Epogen called Retacrit that is was approved in the EU in 2008.
Other Neupogen biosimilars in Europe are NVS’ Zarzio (#msg-52296278) and Teva’s TevaGrastim and RatioGrastim.
In the US, Teva has submitted a conventional BLA (i.e. not an abbreviated BLA under the FDA’s new regulatory pathway for FoB’s) for a Neupogen knockoff called XM102, which is essentially the same drug as TevaGrastim.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.